A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

Frans V Suurs; Marjolijn N Lub-de Hooge; Elisabeth G E de Vries; Derk Jan A de Groot

doi:10.1016/j.pharmthera.2019.04.006

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

Frans V Suurs, Marjolijn N Lub-de Hooge, Elisabeth G E de Vries, Derk Jan A de Groot

Research output: Contribution to journal › Review article › peer-review

222 Citations (Scopus)

2061 Downloads (Pure)

Abstract

Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of which has reached phase 3. These bsAbs show great variability in design and mechanism of action. The various designs are often linked to the mechanisms of actions. The majority of bsAbs engage immune cells to destroy tumor cells. However, some bsAbs are also used to deliver payloads to tumors or to block tumor signaling pathways. This review provides insight into the choice of construct for bsAbs, summarizes the clinical development of bsAbs in oncology and identifies subsequent challenges. (C) 2019 The Authors. Published by Elsevier Inc.

Original language	English
Pages (from-to)	103-119
Number of pages	17
Journal	Pharmacology & Therapeutics
Volume	201
Early online date	24-Apr-2019
DOIs	https://doi.org/10.1016/j.pharmthera.2019.04.006
Publication status	Published - Sept-2019

Keywords

Bispecific antibody (bsAb)
Antibody constructs
Oncology
Cancer immunotherapy
Clinical trials
SINGLE-CHAIN ANTIBODY
MEDULLARY-THYROID CARCINOMA
T-CELLS
MONOCLONAL-ANTIBODIES
BITE ANTIBODY
PHASE-I
PRETARGETED RADIOIMMUNOTHERAPY
ANTITUMOR-ACTIVITY
TARGETED DELIVERY
ANTIGEN-BINDING

Access to Document

10.1016/j.pharmthera.2019.04.006Licence: CC BY

A review of bispecific antibodies and antibody constructs in oncology and clinical challengesFinal publisher's version, 1.9 MBLicence: CC BY

Handle.net

Persistent link

Cite this

@article{e96d916d5374422aba831d2f0edc4e8e,

title = "A review of bispecific antibodies and antibody constructs in oncology and clinical challenges",

abstract = "Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of which has reached phase 3. These bsAbs show great variability in design and mechanism of action. The various designs are often linked to the mechanisms of actions. The majority of bsAbs engage immune cells to destroy tumor cells. However, some bsAbs are also used to deliver payloads to tumors or to block tumor signaling pathways. This review provides insight into the choice of construct for bsAbs, summarizes the clinical development of bsAbs in oncology and identifies subsequent challenges. (C) 2019 The Authors. Published by Elsevier Inc.",

keywords = "Bispecific antibody (bsAb), Antibody constructs, Oncology, Cancer immunotherapy, Clinical trials, SINGLE-CHAIN ANTIBODY, MEDULLARY-THYROID CARCINOMA, T-CELLS, MONOCLONAL-ANTIBODIES, BITE ANTIBODY, PHASE-I, PRETARGETED RADIOIMMUNOTHERAPY, ANTITUMOR-ACTIVITY, TARGETED DELIVERY, ANTIGEN-BINDING",

author = "Suurs, {Frans V} and {Lub-de Hooge}, {Marjolijn N} and {de Vries}, {Elisabeth G E} and {de Groot}, {Derk Jan A}",

year = "2019",

month = sep,

doi = "10.1016/j.pharmthera.2019.04.006",

language = "English",

volume = "201",

pages = "103--119",

journal = "Pharmacology & Therapeutics",

issn = "0163-7258",

publisher = "PERGAMON-ELSEVIER SCIENCE LTD",

}

TY - JOUR

T1 - A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

AU - Suurs, Frans V

AU - Lub-de Hooge, Marjolijn N

AU - de Vries, Elisabeth G E

AU - de Groot, Derk Jan A

PY - 2019/9

Y1 - 2019/9

N2 - Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of which has reached phase 3. These bsAbs show great variability in design and mechanism of action. The various designs are often linked to the mechanisms of actions. The majority of bsAbs engage immune cells to destroy tumor cells. However, some bsAbs are also used to deliver payloads to tumors or to block tumor signaling pathways. This review provides insight into the choice of construct for bsAbs, summarizes the clinical development of bsAbs in oncology and identifies subsequent challenges. (C) 2019 The Authors. Published by Elsevier Inc.

AB - Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of which has reached phase 3. These bsAbs show great variability in design and mechanism of action. The various designs are often linked to the mechanisms of actions. The majority of bsAbs engage immune cells to destroy tumor cells. However, some bsAbs are also used to deliver payloads to tumors or to block tumor signaling pathways. This review provides insight into the choice of construct for bsAbs, summarizes the clinical development of bsAbs in oncology and identifies subsequent challenges. (C) 2019 The Authors. Published by Elsevier Inc.

KW - Bispecific antibody (bsAb)

KW - Antibody constructs

KW - Oncology

KW - Cancer immunotherapy

KW - Clinical trials

KW - SINGLE-CHAIN ANTIBODY

KW - MEDULLARY-THYROID CARCINOMA

KW - T-CELLS

KW - MONOCLONAL-ANTIBODIES

KW - BITE ANTIBODY

KW - PHASE-I

KW - PRETARGETED RADIOIMMUNOTHERAPY

KW - ANTITUMOR-ACTIVITY

KW - TARGETED DELIVERY

KW - ANTIGEN-BINDING

U2 - 10.1016/j.pharmthera.2019.04.006

DO - 10.1016/j.pharmthera.2019.04.006

M3 - Review article

C2 - 31028837

SN - 0163-7258

VL - 201

SP - 103

EP - 119

JO - Pharmacology & Therapeutics

JF - Pharmacology & Therapeutics

ER -

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this